How to Conduct Post-Market Surveillance for Overseas Registration of IVD Products?

Key Summary

Post-market surveillance (PMS) for IVD products registered overseas is critical to ensure ongoing compliance with target country regulations and patient safety. Companies must establish systematic PMS processes based on the regulatory framework of the target country (e.g., EU IVDR, US FDA, GHWP members), including adverse event reporting, vigilance systems, periodic safety update reports (PSUR), field safety corrective actions (FSCA), and more. Key considerations include determining product risk classification, confirming company responsibilities, preparing technical documentation evidence chains, appointing local authorized representatives, and integrating the PMS module into the quality management system.

Common risks include confusing PMS with post-market performance follow-up (PMPF), misunderstanding reporting timelines, unclear local agent responsibilities, and failure to update technical documents promptly. Companies should first verify whether the product falls under medical device regulations, then determine PMS requirements according to risk classification. For example, EU Class D devices require stricter PSUR and PMPF. Data from CE or FDA registrations can be reused but must be localized. For multi-country registrations, it is recommended to establish a unified PMS framework to reduce redundant work and correction risks.

Common Questions and Answers

How should IVD products conduct post-market surveillance after overseas registration?

PMS for IVD products after overseas registration is a critical process to ensure continuous compliance with the regulatory requirements of target countries and to guarantee patient safety. Companies should establish a systematic PMS process based on the target country's regulatory system (e.g., EU IVDR, US FDA, GHWP member states), encompassing adverse event reporting, vigilance systems, periodic safety update reports (PSUR), field safety corrective actions (FSCA), and more. The core lies in determining product risk classification, confirming company responsibilities, preparing evidence chains in technical documentation, appointing local authorized representatives, and integrating the PMS module into the quality management system.

What is the regulatory judgment logic for IVD PMS?

First, confirm whether the product is classified as a medical device or in vitro diagnostic reagent in the target country. For example, the EU IVDR covers all IVDs, while some Middle Eastern countries may classify certain test reagents as drugs. Second, determine the risk classification—EU classes A to D correspond to different PMS requirements: Class D requires PSUR every two years and PMPF; Class C every two years; Class B every three years; Class A no periodic reports. Third, assess whether existing quality management systems (e.g., ISO 13485, MDSAP) include a PMS module. Finally, verify whether technical documentation, risk management reports, clinical evidence, and labeling can be reused, with special attention to whether the PMPF plan needs localization adjustments. For GHWP member states, it is recommended to adopt the ASEAN Medical Device Directive or local FDA-like PMS requirements. If registering in multiple countries, a unified PMS framework should be established first, then fine-tuned for each country's differences to avoid duplication.

What are the core documents needed for PMS?

Core PMS documents include: PMS plan and PMS report (regularly updated, usually annually); adverse event and complaint records (reported according to national timelines); PSUR (submitted periodically based on risk classification); PMPF plan and report (especially for high-performance products); continuous compliance review records for labels, instructions, and promotional materials; field safety corrective action (FSCA) documents (e.g., recall notices); communication records with local authorized representatives and annual management review reports. Companies must ensure these documents are consistent with initial registration files and updated promptly with regulatory changes. When reusing existing documents (e.g., CE technical files), format and content localization are required, such as translation into local languages and addition of country-specific statistical methods.

What are common mistakes in IVD PMS?

• Confusing PMS with PMPF: PMS is broad surveillance, while PMPF is active performance tracking; both are required but with different requirements.
• Ignoring reporting timelines: Timelines for serious adverse events vary significantly (e.g., FDA requires 30 days, EU 15 days), leading to omissions or delays.
• Unclear local agent responsibilities: Many companies think agents only handle registration, but agents also bear PMS and local reporting responsibilities; contracts must clarify this.
• Failure to update technical documents synchronously: Product changes (e.g., software upgrades) are not reflected in PMS files, causing audit gaps.
• Neglecting PMS for low-risk products: Class A or I products do not require PSUR but still need complaint handling and basic PMS records.

How to prepare a checklist for IVD PMS?

Before starting a project, companies should use an internal checklist to verify the documentation basis and avoid discovering critical evidence gaps after submission. Steps include: compile target product list, model specifications matrix, and intended use statements; verify whether existing NMPA, CE, FDA, or other market registration documents can be reused; prepare ISO 13485 certificate, test reports, risk management, clinical evaluation, and English instructions; confirm local agent or authorized representative responsibilities, fees, certificate control rights, and exit mechanisms; establish a target country gap assessment table to identify items requiring supplementary testing, translation, notarization, or additional declarations.

Can PMS data from CE registration be used directly in GHWP countries?

Data can be partially reused, but format and language differences must be considered. For example, ASEAN countries accept English PSUR, but China requires Chinese translations. In terms of content, adverse event and performance data can be shared, but local usage data must be collected additionally. Reporting frequency and statistical methods may also differ, so it is advisable to consult local agents for compliance assessment.

Do low-risk IVDs (e.g., Class A) require no PMS at all?

No. Although periodic PSUR is not required, companies must still establish complaint handling and adverse event collection mechanisms and maintain records. If product quality issues or safety events occur, they must be reported to regulatory authorities. Therefore, even low-risk products should maintain basic PMS documentation.

What is the difference between PMS report and PSUR?

A PMS report is usually an annual internal report summarizing all collected PMS data; a PSUR is a safety update report submitted to regulatory authorities, focusing more on safety and risk-benefit assessment, with fixed format and submission cycles. They can be combined but must meet regulatory requirements.

AIMEILI Regulatory Interpretation and Business Impact

The most common misjudgment companies make is viewing PMS merely as a single post-registration 'report submission' action, overlooking its continuous, systematic, and country-specific nature. In the early stages of a project, we recommend first establishing a global unified PMS framework, then conducting compliance screening for target countries. PMS data from CE or FDA can be reused, but for example, the EU IVDR requires PMPF plans to be based on actual clinical use scenarios of the product and cannot simply copy the US PMCF plan.

The local agent is not just a registration front; they are also one of the PMS responsible parties. Certificate control rights (e.g., the notified body for CE certificates) and the change and renewal process must be directly led by the company; otherwise, changes in agents may lead to registration invalidation. For multi-country registrations, adopting a 'core-satellite mapping' strategy—where the core PMS file is maintained by headquarters and country-specific versions are generated through standard conversion mapping—can significantly reduce redundant work and correction risks.

In real projects, companies should break down the issue into five tasks: regulatory judgment, document preparation, evidence reuse, localization conversion, and post-market maintenance, rather than having only one department temporarily compile documents. This approach helps identify documentation gaps earlier and aligns sales, R&D, quality, and regulatory teams on target country requirements. If planning to enter multiple markets simultaneously, it is recommended to first form a unified core technical document, then supplement authorization, labeling, language, forms, and local agent materials for each country. The efficiency of multi-country registration often depends on the uniformity of the initial document framework, not the submission speed of a single country.